Study wrapper · #965
Amylin Revisited: A 5-Year Perspective on Its Emerging Role in the Treatment of Diabesity.
Chung CW, Kim J Journal of obesity & metabolic syndrome. 2026.
DOI: 10.7570/jomes25085PubMed: 41549439
Editor's note
A narrative review summarizing the amylin pathway and its analogs for obesity and type 2 diabetes. Cagrilintide and semaglutide feature as the peptide-relevant agents, with combination therapy associated with weight loss exceeding 15% in trials. Useful as background context rather than primary evidence.
Plain-language abstract
This review discusses amylin biology and the amylin analog cagrilintide, which has been studied for weight loss in obesity, including in combination with semaglutide.
Related coverage
Mixed
Amylin and the renin-angiotensin system: risk or opportunity in amylin-based therapy?
Lancet (London, England)n=——2026
Supported
Co-agonism of GLP-1R and CTR/AMYR in the lateral dorsal tegmental nucleus produces additive effects on homeostatic and motivated feeding.
Physiology & behaviorn=——2026
Supported
Maximizing weight loss with cagrisema: a systematic review and GRADE-assessed meta-analysis of randomized controlled trials.
Naunyn-Schmiedeberg's archives of pharmacologyn=——2026